These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 23818778)

  • 1. Combinatorial evaluation of in vivo distribution of polyanhydride particle-based platforms for vaccine delivery.
    Petersen LK; Huntimer L; Walz K; Ramer-Tait A; Wannemuehler MJ; Narasimhan B
    Int J Nanomedicine; 2013; 8():2213-25. PubMed ID: 23818778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of biocompatibility and administration site reactogenicity of polyanhydride-particle-based platform for vaccine delivery.
    Huntimer L; Ramer-Tait AE; Petersen LK; Ross KA; Walz KA; Wang C; Hostetter J; Narasimhan B; Wannemuehler MJ
    Adv Healthc Mater; 2013 Feb; 2(2):369-78. PubMed ID: 23184561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polyanhydride nanovaccine against swine influenza virus in pigs.
    Dhakal S; Goodman J; Bondra K; Lakshmanappa YS; Hiremath J; Shyu DL; Ouyang K; Kang KI; Krakowka S; Wannemuehler MJ; Won Lee C; Narasimhan B; Renukaradhya GJ
    Vaccine; 2017 Feb; 35(8):1124-1131. PubMed ID: 28117173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of innate immune responses in a pathogen-mimicking manner by amphiphilic polyanhydride nanoparticle adjuvants.
    Petersen LK; Ramer-Tait AE; Broderick SR; Kong CS; Ulery BD; Rajan K; Wannemuehler MJ; Narasimhan B
    Biomaterials; 2011 Oct; 32(28):6815-22. PubMed ID: 21703679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pegylated poly(anhydride) nanoparticles for oral delivery of docetaxel.
    Ruiz-Gatón L; Espuelas S; Larrañeta E; Reviakine I; Yate LA; Irache JM
    Eur J Pharm Sci; 2018 Jun; 118():165-175. PubMed ID: 29597043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cellular Internalization Mechanisms of Polyanhydride Particles: Implications for Rational Design of Drug Delivery Vehicles.
    Phanse Y; Lueth P; Ramer-Tait AE; Carrillo-Conde BR; Wannemuehler MJ; Narasihan B; Bellaire BH
    J Biomed Nanotechnol; 2016 Jul; 12(7):1544-52. PubMed ID: 29337493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conjunctival vaccination against Brucella ovis in mice with mannosylated nanoparticles.
    Da Costa Martins R; Gamazo C; Sánchez-Martínez M; Barberán M; Peñuelas I; Irache JM
    J Control Release; 2012 Sep; 162(3):553-60. PubMed ID: 22846987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preparation, characterization and pharmacokinetic evaluation of rosuvastatin calcium incorporated cyclodextrin-polyanhydride nanoparticles.
    Al-Heibshy FNS; Başaran E; Arslan R; Öztürk N; Vural İ; Demirel M
    Drug Dev Ind Pharm; 2019 Oct; 45(10):1635-1645. PubMed ID: 31342792
    [No Abstract]   [Full Text] [Related]  

  • 9. Lung deposition and cellular uptake behavior of pathogen-mimicking nanovaccines in the first 48 hours.
    Ross KA; Haughney SL; Petersen LK; Boggiatto P; Wannemuehler MJ; Narasimhan B
    Adv Healthc Mater; 2014 Jul; 3(7):1071-7. PubMed ID: 24520022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functionalization promotes pathogen-mimicking characteristics of polyanhydride nanoparticle adjuvants.
    Phanse Y; Carrillo-Conde BR; Ramer-Tait AE; Roychoudhury R; Broderick S; Pohl N; Rajan K; Narasimhan B; Wannemuehler MJ; Bellaire BH
    J Biomed Mater Res A; 2017 Oct; 105(10):2762-2771. PubMed ID: 28556563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and biocompatibility of carbohydrate-functionalized polyanhydride nanoparticles.
    Vela-Ramirez JE; Goodman JT; Boggiatto PM; Roychoudhury R; Pohl NL; Hostetter JM; Wannemuehler MJ; Narasimhan B
    AAPS J; 2015 Jan; 17(1):256-67. PubMed ID: 25421457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of polyanhydride chemistry in particle-based cancer vaccines on the magnitude of the anti-tumor immune response.
    Wafa EI; Geary SM; Goodman JT; Narasimhan B; Salem AK
    Acta Biomater; 2017 Mar; 50():417-427. PubMed ID: 28063991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and Characterization of Rapidly Degrading Polyanhydrides as Vaccine Adjuvants.
    Kelly SM; Mitra A; Mathur S; Narasimhan B
    ACS Biomater Sci Eng; 2020 Jan; 6(1):265-276. PubMed ID: 33463223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of nanovaccine chemistry on humoral immune response kinetics and maturation.
    Haughney SL; Ross KA; Boggiatto PM; Wannemuehler MJ; Narasimhan B
    Nanoscale; 2014 Nov; 6(22):13770-8. PubMed ID: 25285425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amphiphilic polyanhydride nanoparticles stabilize Bacillus anthracis protective antigen.
    Petersen LK; Phanse Y; Ramer-Tait AE; Wannemuehler MJ; Narasimhan B
    Mol Pharm; 2012 Apr; 9(4):874-82. PubMed ID: 22380593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retention of structure, antigenicity, and biological function of pneumococcal surface protein A (PspA) released from polyanhydride nanoparticles.
    Haughney SL; Petersen LK; Schoofs AD; Ramer-Tait AE; King JD; Briles DE; Wannemuehler MJ; Narasimhan B
    Acta Biomater; 2013 Sep; 9(9):8262-71. PubMed ID: 23774257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of CpG-ODN-adjuvanted polyanhydride-based intranasal influenza nanovaccine in pigs.
    Dhakal S; Ghimire S; Renu S; Ross KA; Lakshmanappa YS; Hogshead BT; Bernardo P; Lee CW; Wannemuehler MJ; Narasimhan B; Renukaradhya GJ
    Vet Microbiol; 2019 Oct; 237():108401. PubMed ID: 31585639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. pH-Responsive Microencapsulation Systems for the Oral Delivery of Polyanhydride Nanoparticles.
    Sharpe LA; Vela Ramirez JE; Haddadin OM; Ross KA; Narasimhan B; Peppas NA
    Biomacromolecules; 2018 Mar; 19(3):793-802. PubMed ID: 29443509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design of a protective single-dose intranasal nanoparticle-based vaccine platform for respiratory infectious diseases.
    Ulery BD; Kumar D; Ramer-Tait AE; Metzger DW; Wannemuehler MJ; Narasimhan B
    PLoS One; 2011 Mar; 6(3):e17642. PubMed ID: 21408610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of Immune Responses to an Inactivated Avian Influenza Virus Vaccine Adjuvanted with Nanoparticles Containing CpG ODN.
    Singh SM; Alkie TN; Abdelaziz KT; Hodgins DC; Novy A; Nagy É; Sharif S
    Viral Immunol; 2016 Jun; 29(5):269-75. PubMed ID: 27077969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.